Viatris Inc. reports developments for a global healthcare company with a portfolio spanning generics, established brands and innovative medicines. News commonly covers quarterly results, guidance, cash deployment, dividends, capital allocation and management changes, alongside product launches and pipeline updates across major therapeutic areas.
Company updates also include scientific presentations and regulatory actions tied to specific medicines and candidates, including Effexor in Japan, ophthalmology programs such as phentolamine ophthalmic solution and RYZUMVI, and an investigational low-dose estrogen combined hormonal contraceptive weekly patch. Viatris was formed through the combination of Mylan and Pfizer's Upjohn business and operates with global centers in the U.S., China and India.
Ingram Micro Holding (NYSE: INGM) will join the S&P SmallCap 600 before trading opens on November 17, 2026. It will replace Pacira BioSciences (NASD: PCRX), with Ingram classified in Information Technology and Pacira in Health Care. S&P 500 constituent Viatris (NASD: VTRS) is acquiring Pacira in a deal expected to close soon, pending final closing conditions.
Viatris (VTRS) will participate in fireside chats at three upcoming healthcare investor conferences in November and December 2026.
The sessions are UBS Global Biopharma on November 17 at 10 a.m. GMT / 5 a.m. ET; Jefferies Global Healthcare on November 18 at 9 a.m. GMT / 4 a.m. ET; and the 9th Annual Evercore Healthcare Conference on December 1 at 8:45 a.m. ET. Live sessions and limited-time replays will be available at investor.viatris.com.
Viatris (Nasdaq: VTRS) reported third-quarter 2026 revenue of $3.75 billion, essentially flat compared with the same quarter a year earlier. The GAAP net loss widened to $325.3 million from $128.2 million, while adjusted earnings per share rose 6% to $0.71. Operating cash flow increased 21% to $899.4 million.
The company raised its 2026 guidance midpoints, targeting revenue of $14.8 billion and adjusted earnings per share of $2.60, excluding any Pacira contribution. Viatris agreed to acquire Pacira BioSciences for $36.50 per share in cash, an aggregate equity value of $1.65 billion, with closing expected by the end of November 2026.
RYZUMVI received U.S. approval for presbyopia, and WAKIX received Japanese approvals. Viatris suspended manufacturing at its Nashik facility in October. Supply constraints reduced third-quarter revenue by approximately $100 million; the company anticipates approximately the same fourth-quarter impact.
Viatris (Nasdaq: VTRS) declared a quarterly dividend of $0.12 per common share, payable December 16, 2026, to eligible shareholders.
The board declared the dividend on November 2, 2026. Shareholders must be on record at the close of business on November 23, 2026. Viatris will report third-quarter 2026 results on November 5, with an 8:30 a.m. ET webcast covering results and the planned acquisition of Pacira BioSciences.
Viatris (VTRS) has commenced a tender offer through its wholly owned subsidiary to acquire Pacira BioSciences (PCRX) for $36.50 per share. The cash payment is net of applicable withholding taxes and without interest. The offer follows the Oct. 8, 2026 merger agreement.
The offer and withdrawal rights expire one minute following 11:59 p.m. Eastern Time on Nov. 16, 2026, unless extended or earlier terminated. Pacira's board unanimously recommends tendering. Completion requires tendered shares plus purchaser-affiliate holdings to represent at least one share more than 50% of outstanding shares, expiration or termination of the applicable antitrust waiting period, and no prohibiting legal restraint. There is no financing condition. Following completion, Pacira would become a wholly owned Viatris subsidiary through a merger requiring no Pacira stockholder vote.
Viatris (Nasdaq: VTRS) received U.S. FDA approval for RYZUMVI to treat presbyopia, the age-related loss of near focusing ability, in adults.
The approval expands the indications for phentolamine ophthalmic solution 0.75%, which is already approved in the United States to treat pharmacologically induced mydriasis, or drug-induced pupil dilation. Viatris is exploring a potential U.S. partner to commercialize RYZUMVI for presbyopia. A global licensing agreement with Opus Genetics provides for development of the solution and grants Viatris exclusive U.S. commercialization rights.
The product's warnings advise against use in patients with active eye inflammation and caution against touching the vial tip to the eye or other surfaces to avoid injury or contamination.
Pacira BioSciences (PCRX) agreed to an acquisition by Viatris (VTRS) for $36.50 per share in cash, through a tender offer.
The agreement values Pacira's equity at $1.65 billion. A second-step merger would acquire shares not tendered for the same consideration. Both boards unanimously approved the transaction, and Pacira's board recommends tendering shares. Closing is expected by the end of 2026, subject to a majority of outstanding shares being tendered and expiration of the applicable regulatory waiting period.
Pacira generated approximately $746 million in revenue and $177 million in adjusted EBITDA, an adjusted earnings measure before interest, taxes, depreciation and amortization, in the twelve months ended June 30, 2026. Its marketed medicines include EXPAREL and ZILRETTA. Viatris expects to expand their reach across selected international markets.
Viatris (VTRS) will report its third-quarter 2026 financial results on November 5, 2026, with executives hosting a call that day.
The conference call and live webcast will begin at 8:30 a.m. ET. Investors and the public can listen at investor.viatris.com, where a webcast replay will also be available.
Viatris (VTRS) was named to Forbes' World's Best Employers list for the sixth consecutive year. The Forbes-Statista ranking drew on an independent survey of more than 300,000 participants across over 50 countries. Respondents rated their willingness to recommend their employer and could evaluate other aspects of employment.
Viatris (VTRS) received approval from Japan's Ministry of Health, Labour and Welfare for WAKIX (pitolisant) to treat excessive daytime sleepiness (EDS) associated with obstructive sleep apnea syndrome in patients already receiving airway obstruction treatment, and for narcolepsy types 1 and 2, with and without cataplexy.
WAKIX is described as the first histamine H3 receptor antagonist/inverse agonist approved in Japan for these indications and is not classified as a controlled substance. The approval is based on positive results from domestic Phase 3 clinical trials in Japan and multiple international clinical studies in narcolepsy and in obstructive sleep apnea patients experiencing EDS despite continuous positive airway pressure (CPAP) therapy. Viatris characterizes this as advancing its innovative medicines portfolio in Japan.